AR059686A1 - Piperazinas terapeuticas - Google Patents

Piperazinas terapeuticas

Info

Publication number
AR059686A1
AR059686A1 ARP070100831A ARP070100831A AR059686A1 AR 059686 A1 AR059686 A1 AR 059686A1 AR P070100831 A ARP070100831 A AR P070100831A AR P070100831 A ARP070100831 A AR P070100831A AR 059686 A1 AR059686 A1 AR 059686A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
alkoxy
aryl
halo
Prior art date
Application number
ARP070100831A
Other languages
English (en)
Inventor
Terence P Keenan
Alan P Kaplan
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of AR059686A1 publication Critical patent/AR059686A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de piperazina, composiciones que comprenden tales compuestos, y métodos de preparacion del compuesto. Los compuestos son inhibidores e la funcion PDE4 y son utiles para mejorar la funcion cognitiva, retardo mental, trastornos psicoticos y neuroticos y tumor cerebral. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula 1: en donde: R1 es H, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, alcanoiloxi C1-6, cicloalquilo C3-8, cicloalquil C3-8- alquilo C1-6, halo(C1-6)alquilo, arilo, aril(C1-6)alquilo, aril(C1-6)alcoxi, aril(C1-6)alcanoilo, het, het(C1-6)alquilo, het(C1-6)alcoxi, o het(C1-6)alcanoilo; n es 1 o 2; m es 1 o 2; W es O, S, o dos hidrogenos; X es O o N-Y-R4, Y es un enlace directo, -CH2-, -C(=O)-, -C(=S)-, -O-, -C(=O)O-, - OC(=O)-, -C(=O)Nra-, -S-, -S(=O), -S(=O)2, o -S(=O)2Nra-; R4 es H, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, hidroxi, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, halo(C1-6)alquilo, hidroxi(C1- 6)alquilo, alcoxicarbonilo C1-6, carboxi, arilo, aril(C1-6)alquilo, het, NRdRe, C(=O)NRdRe, NRdRe(C1-6)alquilo, o het(C1-6)alquilo; Ra es H, alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6-alquilo C2-6, o cicloalquil C3-8-alquilo C1-6; Z es un anillo fenilo sustituido con uno o más sustituyentes seleccionados en forma independiente entre alquilo C1-6, halo(C1-6)alquilo, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, alcoxi C1-6, halo(C1-6)alcoxi, cicloalquiloxi C3-8, y cicloalquil C3-8-alcoxi C1-6; o Z es un anillo fenilo que está fusionado con un sistema de anillo mono o bicíclico saturado, parcialmente insaturado o aromático que comprende entre aproximadamente 3 y aproximadamente 8 átomos seleccionados entre carbono, oxígeno, y NRb, en donde el sistema de anillo mono o bicíclico de Z está opcionalmente sustituido con uno o más Rc, y en donde el anillo fenilo que está fusionado con el sistema de anillo mono o bicíclico está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre alquiloC1-6, halo (C1-6)alquilo, cicloalquilo C3-8, cicloalquil 3-8-alquilo C1-6, alcoxi C1-6, halo(C2-6)alcoxi, cicloalquiloxi C3-8, cicloalquil C3-8-alcoxi C1-6; Rb está ausente , H, alquilo C1-6, cicloalquilo C3-8, alcoxi C1-6-alquilo C2-6, o cicloalquil C3-8-alquilo C1-6; Rc es alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, alcanoiloxi C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, halo(C1-6)alquilo, arilo, aril(C1-6)alquilo, aril(C1-6)alcoxi, aril(C1-6)alcanoilo, het, het(C1-6)alquilo, het(C1-6)alcoxi, o het(C1-6)alcanoilo; cada Rd y Re es en forma independiente H, hidroxi, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6,alqueniloxi C2-6, alquiniloxi C2-6, alcanoilo C1-6, alcoxicarbonilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, arilo, aril (C1-6)alquilo, NRfRg, o aril(C1-6)alcoxi; y cada Rf y Rg es en forma independiente H, alquilo C1-6, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, arilo, aril(C1-6)alquilo, o aril(C1-6)alcoxi; o Rf y Rg junto con el nitrogeno al cual están unidos forman un anillo pirrolidino, piperidino, piperazino, morfolino, o tiomorfolino; en donde cualquier grupo arilo o het de R1 o R4 está opcionalmente sustituido con uno o más sustituyentes seleccionados en forma independiente entre alquilo C1-6, fenilo, alcoxi C1-6, alcanoilo C1-6, alcoxicarbonilo C1-6, alcanoiloxi C1-6, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-6, halo(C1-6)alquilo, cicloalquiloxi C3-8, cicloalquil C3-8-alcoxi C1-6, halo(C2-6)alcoxi, ciano, nitro, halo, carboxi o NRdRe; y en donde el anillo con un contenido de X está opcionalmente sustituido sobre carbon con uno o más halo, alquilo C1-6, o alcoxi C1-6, o una sal aceptable para uso farmacéutico del mismo.
ARP070100831A 2006-02-28 2007-02-28 Piperazinas terapeuticas AR059686A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77729106P 2006-02-28 2006-02-28

Publications (1)

Publication Number Publication Date
AR059686A1 true AR059686A1 (es) 2008-04-23

Family

ID=38279005

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100831A AR059686A1 (es) 2006-02-28 2007-02-28 Piperazinas terapeuticas

Country Status (15)

Country Link
US (4) US7829713B2 (es)
EP (2) EP1989188B1 (es)
JP (1) JP2009528363A (es)
CN (1) CN101490017B (es)
AR (1) AR059686A1 (es)
AU (1) AU2007221021B2 (es)
BR (1) BRPI0708337A2 (es)
CA (1) CA2644069A1 (es)
ES (1) ES2462240T3 (es)
HK (1) HK1185063A1 (es)
IL (1) IL193674A0 (es)
NZ (1) NZ570844A (es)
SG (2) SG171634A1 (es)
TW (1) TW200804309A (es)
WO (1) WO2007100852A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200804309A (en) * 2006-02-28 2008-01-16 Helicon Therapeutics Inc Therapeutic piperazines
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
AR065709A1 (es) * 2007-03-12 2009-06-24 Biolipox Ab Piperidinonas y composiciones farmaceuticas que las contienen usadas para el tratamiento de la inflamacion. procesos de obtencion.
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
DK2142529T3 (da) 2007-04-27 2014-02-10 Purdue Pharma Lp Trpv1-antagonister og anvendelser deraf
AR077969A1 (es) * 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
EP2539706B1 (en) * 2010-02-24 2015-03-04 Research Triangle Institute Arylpiperazine opioid receptor antagonists
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
RS55701B1 (sr) 2011-06-22 2017-07-31 Purdue Pharma Lp Trpv1 antagonisti koji uključuju dihidroksi supstituent i njihove upotrebe
KR102148355B1 (ko) 2012-07-27 2020-08-26 사토 파머슈티컬 가부시키가이샤 디플루오로메틸렌 화합물
CA2894130A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
HUE040323T2 (hu) 2012-12-21 2019-02-28 Epizyme Inc PRMT5-inhibitorok és alkalmazásaik
JP2016505597A (ja) 2012-12-21 2016-02-25 エピザイム,インコーポレイティド Prmt5阻害剤およびその使用
EP2970212B1 (en) 2013-03-14 2018-04-25 Dart Neuroscience (Cayman) Ltd. Substituted pyridine and pyrazine compounds as pde4 inhibitors
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
BR112022008113A2 (pt) 2019-10-31 2022-07-19 Escape Bio Inc Formas sólidas de um modulador de receptor s1p

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996507A (en) * 1959-09-09 1961-08-15 Abbott Lab Piperazine compounds
US3306903A (en) * 1965-10-07 1967-02-28 Council Scient Ind Res 1-aminopyridyl-4-(phenyl or pyridyl)-piperazines and intermediates
FR2262964B1 (es) * 1973-04-05 1978-07-28 Synthelabo
DE2345422C2 (de) * 1973-09-08 1983-12-22 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte Isochinolyl-arylpiperazine diese enthaltende Arzneimittel sowie Verfahren zu deren Herstellung
AT330777B (de) * 1973-09-08 1976-07-26 Thomae Gmbh Dr K Verfahren zur herstellung von neuen isochinolinderivaten und deren salzen
GB1575904A (en) * 1976-04-23 1980-10-01 Lilly Industries Ltd Phenyl piperazines
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US4666911A (en) * 1981-07-14 1987-05-19 Taiho Pharmaceutical Company Limited Allophanoylpiperazine compound and analgesic composition containing same as active ingredient
FR2533212A1 (fr) * 1982-09-22 1984-03-23 Lipha Benzo-et thieno-triazine-1,2,3 ones-4 procedes de preparation et medicaments les contenant
FR2551753B2 (fr) * 1982-09-22 1986-02-28 Lipha Benzotriazine-1,2,3-ones-4, procede de preparation et medicaments les contenant
DE3442860A1 (de) * 1984-11-24 1986-05-28 Kali-Chemie Pharma Gmbh, 3000 Hannover 5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3- on-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE81975T1 (de) * 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
US4845100A (en) * 1985-04-12 1989-07-04 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US4960776A (en) 1987-01-28 1990-10-02 A. H. Robins Company, Inc. 4-aryl-N-(alkylaminoalkyl, heterocyclicamino and heterocyclicamino)alkyl)-1-piperazinecarboxamides
US5204482A (en) * 1988-07-28 1993-04-20 Hoffman-Laroche Inc. Compounds for treating and preventing cognitive diseases and depression and methods of making same
US5086055A (en) * 1990-12-24 1992-02-04 A. H. Robins Company, Incorporated Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives useful in the treatment of allergic conditions
TW197429B (es) * 1991-05-01 1993-01-01 Dtsuka Seiyaku Kk
FR2680172B1 (fr) * 1991-08-05 1993-11-19 Fabre Medicament Pierre Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
DE4241563A1 (de) * 1992-12-10 1994-06-16 Basf Ag Neue Triazolochinazoline, ihre Herstellung und Verwendung
JPH10152470A (ja) * 1996-09-25 1998-06-09 Yoshitomi Pharmaceut Ind Ltd ピペラジン化合物
DE19744026A1 (de) * 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
AU754734B2 (en) 1997-11-04 2002-11-21 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
EP2258689A1 (en) 2000-03-16 2010-12-08 Biolipox AB Benzylated PDE4 inhibitors
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
KR20040012851A (ko) * 2001-05-22 2004-02-11 뉴로젠 코포레이션 멜라닌 농축성 호르몬 수용체 리간드: 치환된1-벤질-4-아릴 피페라진 유사체
AU2002326948A1 (en) 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
WO2004013130A1 (en) 2002-08-02 2004-02-12 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
DE60330150D1 (en) 2002-08-08 2009-12-31 Memory Pharmaceutical Corp Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
PT1539753E (pt) * 2002-09-16 2009-12-10 Glaxo Group Ltd Compostos de pirazolo(3,4-b)piridina e sua utilização como inibidores da fosfodiesterase
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
DE10315571A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
US20050250789A1 (en) * 2004-04-20 2005-11-10 Burns David M Hydroxamic acid derivatives as metalloprotease inhibitors
US7585859B2 (en) * 2004-05-06 2009-09-08 Plexxikon, Inc. PDE4B inhibitors and uses therefor
US7429666B2 (en) 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists
EP1807391A4 (en) 2004-10-29 2010-01-06 Astrazeneca Ab NOVEL SULFONAMIDE DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND FOR THE TREATMENT OF INFLAMMATORY DISEASES
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
KR20080028964A (ko) 2005-06-27 2008-04-02 엑셀리시스, 인코포레이티드 피라졸계 lxr 변조제
CA2621275A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
TW200804309A (en) * 2006-02-28 2008-01-16 Helicon Therapeutics Inc Therapeutic piperazines
EP2060575A1 (de) * 2006-04-19 2009-05-20 Boehringer Ingelheim International GmbH Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
CA2722582A1 (en) 2007-11-21 2009-05-28 Decode Genetics Ehf. Biaryl pde4 inhibitors for treating inflammation

Also Published As

Publication number Publication date
EP1989188A1 (en) 2008-11-12
IL193674A0 (en) 2009-05-04
US8338405B2 (en) 2012-12-25
EP2562168B1 (en) 2014-04-16
EP1989188B1 (en) 2015-07-22
SG171635A1 (en) 2011-06-29
US8501745B2 (en) 2013-08-06
US7829713B2 (en) 2010-11-09
US20110065688A1 (en) 2011-03-17
SG171634A1 (en) 2011-06-29
AU2007221021A1 (en) 2007-09-07
HK1185063A1 (en) 2014-02-07
US20140038945A1 (en) 2014-02-06
EP2562168A1 (en) 2013-02-27
CN101490017A (zh) 2009-07-22
BRPI0708337A2 (pt) 2011-05-24
ES2462240T3 (es) 2014-05-22
AU2007221021B2 (en) 2013-01-17
US20070203124A1 (en) 2007-08-30
JP2009528363A (ja) 2009-08-06
WO2007100852A1 (en) 2007-09-07
CA2644069A1 (en) 2007-09-07
US20110065689A1 (en) 2011-03-17
NZ570844A (en) 2011-11-25
CN101490017B (zh) 2013-01-23
TW200804309A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
AR059686A1 (es) Piperazinas terapeuticas
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
ES2666870T3 (es) Derivado de dispiropirrolidina
AR073920A1 (es) Derivados urea de nortropanos sustituidos, medicamentos que contienen dichos compuestos , su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa y proceso para su preparacion.
PE20190811A1 (es) Derivados de pirazolopirimidinas como inhibidor de quinasa
AR066502A1 (es) Compuestos amino- heterociclicos
AR077434A1 (es) Compuestos para la reduccion de produccion de beta - amiloide
AR088970A1 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
CO2018008799A2 (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de jak
CL2007001555A1 (es) Compuestos derivados de 4-amino-pirido[3,2-e]pirazinas; inhibidores de fosfodiesterasa 10 (pde10); procedimeinto de preparacion; composicion framaceutica; combinacion farmaceutica, y sus uso en el tratamiento de trastornos neurologicos y psiquiatricos, tales como esquizofrenia y otros trastornos psicoticos.
AR057984A1 (es) DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE
AR071300A1 (es) Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento
AR041734A1 (es) Compuestos de alquino con efecto antagonico de la hcm y medicamentos que contienen estos compuestos
AR034264A1 (es) Derivados azepino(4,5-b)indol sustituidos y composiciones farmaceuticas
PA8615701A1 (es) Derivados de dihidrobenzofuranilo alcanamina y metodos para su uso.
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
AR077796A1 (es) Moduladores de receptores de glutamato metabotropicos
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
AR085316A1 (es) Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas
RU2019143759A (ru) Новое соединение бифенила или его соль
ECSP066459A (es) Miméticos de glucocorticoides, métodos de preparación, composiciones farmacéuticas y usos de los mismos
AR051395A1 (es) Derivados de imidazo- benzodiazepina, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos, y usos en terapeutica
AR049276A1 (es) Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen
AR076688A1 (es) Derivados de isoquinolin-1(2h)-ona

Legal Events

Date Code Title Description
FB Suspension of granting procedure